[{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT-1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Sonire therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Sonire therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonire therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonire therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Eli Lilly"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum Leap Healthcare \/ Athenex","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Athenex"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apotex Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kexing Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Merck & Co"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"IND Enabling","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boston Scientific \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Fulgent Pharma","sponsor":"Fulgent Genetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Fulgent Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Fulgent Pharma \/ Fulgent Genetics","highestDevelopmentStatusID":"6","companyTruncated":"Fulgent Pharma \/ Fulgent Genetics"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Fidia Farmaceutici Spa \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fidia Farmaceutici Spa \/ Inapplicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Boryeong","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Boryeong","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Boryeong"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Inceptua Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inceptua Group \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Inceptua Group \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0.69999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0.69999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Catalyst Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Catalyst Health Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Catalyst Health Ventures"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ US Biotest","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ US Biotest"},{"orgOrder":0,"company":"Surmodics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Abbott Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Inapplicable"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Huons CO., LTD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Huons CO., LTD","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Huons CO., LTD"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGF1\/VEGF2\/VEGF3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Adlai Nortye","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Adlai Nortye","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Adlai Nortye"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Eoc Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Eoc Pharma"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK-4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Oncolytics Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Tangdu Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Tangdu Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tangdu Hospital \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tangdu Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Sandoz B2B"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Pharmapark"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFH018","moa":"||TGF-beta-1","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"||PTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Genelux","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genelux \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Centus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase II","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"GATC Health","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"GATC Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GATC Health \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GATC Health \/ Lisata Therapeutics"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CTGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Gemcitabine","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.52000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series B Financing","leadProduct":"Carboplatin","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ MPM BioImpact"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rebastinib","moa":"||ABL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Cinrebafusp Alpha","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"AO-176","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Intravenous Injection","sponsorNew":"Arch Oncology \/ Eventide Asset Management","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Eventide Asset Management"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AO-176","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Arch Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BW Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Undisclosed","graph3":"BW Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BW Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BW Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IPN60090","moa":"||Glutaminase-1","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NovoTTF-100L","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"Imunon","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Silicon Valley Bank","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"OncoQuest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoQuest \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Inapplicable"},{"orgOrder":0,"company":"OncoQuest","sponsor":"Dual Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Divestment","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0.38,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoQuest \/ Dual Industrial","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Dual Industrial"},{"orgOrder":0,"company":"Shenzhen Hepalink Pharmaceutical","sponsor":"Orient EuroPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Hepalink Pharmaceutical","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ EIC Accelerator"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hikma Pharmaceuticals \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Pharmaceuticals \/ CanariaBio"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Aravive","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Private Placement","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ BVF Partners"},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Specialised Therapeutics \/ CanariaBio"},{"orgOrder":0,"company":"Greenfire Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GRN-300","moa":"||SIK2\/SIK3","graph1":"Oncology","graph2":"Phase I","graph3":"Greenfire Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Greenfire Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Greenfire Bio \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qilu Pharmaceutical \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Lisata Therapeutics"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ CytRx Corporation"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ CytRx Corporation"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pyxis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Intratumoral Infusion","sponsorNew":"VCN Biosciences \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Grifols International"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"VCN Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Theriva Biologics \/ VCN Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ VCN Biosciences"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Termination","leadProduct":"Canerpaturev","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Takara Bio \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"||HGF IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3-beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3-beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3-beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purple Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Purple Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kitov Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Kitov Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Caladrius Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Caladrius Biosciences"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ University of Sydney"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IM156","moa":"||Protein complex-1","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoMet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMet \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ European Investment Bank"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"||AKT\/EGFR\/MAPK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Golden Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Golden Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CTGF","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CTGF","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Craig-Hallum Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Craig-Hallum Capital Group","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Craig-Hallum Capital Group"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asparagine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||FAK","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immunering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunering","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunering \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunering \/ Inapplicable"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||TORC1\/TORC2","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Faeth Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Abraxane","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ National Cancer Institute"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Inapplicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Nucleai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Nucleai","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Nucleai"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Toray Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||CAPRIN1","graph1":"Oncology","graph2":"Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Toray Industries","highestDevelopmentStatusID":"8","companyTruncated":"Bolt Biotherapeutics \/ Toray Industries"},{"orgOrder":0,"company":"Akeso","sponsor":"Dawnrays Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK109","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Dawnrays Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Dawnrays Pharmaceutical"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nab-Paclitaxel","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DLL4\/VEGF-A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DLL4\/VEGF-A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3-beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Tumor Stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Tumor Stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||HER2\/Topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Tumor Stroma","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Nanjing King-friend Biochemical Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Meitheal Pharmaceuticals \/ Nanjing King-friend Biochemical Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Meitheal Pharmaceuticals \/ Nanjing King-friend Biochemical Pharmaceutical"}]
Find Clinical Drug Pipeline Developments & Deals for Paclitaxel
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
